# PARP inhibition in cancer therapy

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11914 |
| Works | 247 |

## Topic papers all

Showing 15 of 247.

- [Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers](https://scholariq.org/papers/inhibition-of-poly-adp-ribose-polymerase-in-tumors-from-i-brca-i-mutation/)
- [Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers](https://scholariq.org/papers/risks-of-breast-ovarian-and-contralateral-breast-cancer-for-i-brca1-i-and-i/)
- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Systematic identification of genomic markers of drug sensitivity in cancer cells](https://scholariq.org/papers/systematic-identification-of-genomic-markers-of-drug-sensitivity-in-cancer-cells/)
- [Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer](https://scholariq.org/papers/neoadjuvant-chemotherapy-or-primary-surgery-in-stage-iiic-or-iv-ovarian-cancer/)
- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer](https://scholariq.org/papers/dna-repair-defects-and-olaparib-in-metastatic-prostate-cancer/)
- [Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors](https://scholariq.org/papers/trapping-of-parp1-and-parp2-by-clinical-parp-inhibitors/)
- [Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation](https://scholariq.org/papers/talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-i-brca-i/)
- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-iii-trial-of-carboplatin-and-paclitaxel-compared-with-cisplatin-and/)
- [Epithelial ovarian cancer](https://scholariq.org/papers/epithelial-ovarian-cancer/)

## Topic primary papers

Showing 15 of 91.

- [Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers](https://scholariq.org/papers/inhibition-of-poly-adp-ribose-polymerase-in-tumors-from-i-brca-i-mutation/)
- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Systematic identification of genomic markers of drug sensitivity in cancer cells](https://scholariq.org/papers/systematic-identification-of-genomic-markers-of-drug-sensitivity-in-cancer-cells/)
- [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://scholariq.org/papers/niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer/)
- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
- [Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/niraparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors](https://scholariq.org/papers/trapping-of-parp1-and-parp2-by-clinical-parp-inhibitors/)
- [Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation](https://scholariq.org/papers/talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-i-brca-i/)
- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer](https://scholariq.org/papers/adjuvant-olaparib-for-patients-with-i-brca1-i-or-i-brca2-i-mutated-breast-cancer/)
- [Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation](https://scholariq.org/papers/olaparib-monotherapy-in-patients-with-advanced-cancer-and-a-germline-i-brca1-2-i/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.